Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis. [PDF]
Orphanet J Rare Dis, 2022 Background Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy.
Liu T +7 more
europepmc +4 more sources
Synovial Non-langerhans Cell Histiocytosis of the Shoulder: A Case Report and Review of the Literature. [PDF]
J Orthop Case Rep, 2020 Histiocytoses are rare disorders and most orthopedic surgeons are unfamiliar with this diagnosis. We report a case of synovial non-Langerhans cell histiocytosis (LCH) located in the shoulder, which has not been reported in the literature previously.A 24-year-old female patient presented to our clinic with shoulder pain and decreased range of motion ...
Huri G +3 more
europepmc +4 more sources
A rare cutaneous lesion in the neonatal period: The non-Langerhans cell histiocytosis
Marmara Medical Journal, 2020 The non-Langerhans cell histiocytosis (non-LCH) is a group of diseases characterized by cutaneous involvement in the neonatal period. The non-LCH affects less than 1 in 200,000 children born each year. A definitive diagnosis is important for the treatment of the disease.
Adnan Barutçu +3 more
openalex +5 more sources
PAPULAR HISTIOCYTOSIS OF HEAD : TYPE OF NON - LANGERHANS CELLS HISTIOCYTOSIS [PDF]
Journal of Evolution of Medical and Dental Sciences, 2014 Papular histiocytosis of the head also known as benign cephalic histiocytosis is a rare, self-limiting histiocytosis that typically starts in early childhood. 1 Erythematous macules, papules and nodules develop on cheeks and spread to the forehead, earlobes and neck. Lesions are asymptomatic, gradually become reddish brown and may spread to involve the
Anil Kumar Gupta, Gaurav Murti
openalex +2 more sources
Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis [PDF]
Orphanet Journal of Rare Diseases, 2021 Abstract Background Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy.
Ting Liu +7 more
openalex +6 more sources
MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis
Blood, 2019 Background: Activation of the MAPK pathway through BRAF mutations or other molecular alterations is a hallmark of the non-Lagerhans cell histiocytosis (non-LCH) such Erdheim-Chester disease (ECD) or Rosai-Dorfman disease (RDD). Conventional clinical molecular testing of tumor tissue fails to identify targetable molecular alteration in about one third ...
Filip Janků +5 more
openalex +3 more sources
Blood Advances, 2023 Abstract Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs), for which therapeutic options are limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histiocytosis hallmark and correlates with a favorable response to BRAF inhibitors ...
Ashley Aaroe +12 more
openalex +3 more sources
Extensive reactive cutaneous histiocytic infiltrate resembling non-Langerhans cell histiocytosis as the presenting sign of underlying vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome. [PDF]
JAAD Case Rep, 2023 Wang CX +3 more
europepmc +2 more sources
A RARE CASE OF PULMONARY NON-LANGERHANS CELL HISTIOCYTOSIS [PDF]
Chest, 2020 Victoria González +3 more
openalex +3 more sources
Blood, 2005 AbstractErdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and more than half of the patients succumb within 3 years. Because interferon-α promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would
Fadi Braiteh +3 more
openalex +4 more sources